Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

Johnson & Johnson Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis

Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), has announced results from the

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a

Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection

Scientists have revealed data from their final analysis of Johnson & Johnson's (NYSE: JNJ) COVID-19 Phase 3 study, showing the vaccine may be even less effective in the longer term.

Johnson & Johnson Halts Production Of Its COVID-19 Vaccine: NYT

Johnson & Johnson (NYSE: JNJ) quietly shut down the only plant making usable batches of its COVID-19 vaccine, the

Hopeful Golden Cross Forms On Johnson & Johnson's Chart

If history is any guide, there may be good fortune ahead for shares of Johnson & Johnson (NYSE:JNJ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

Johnson & Johnson (NYSE: JNJ) and the three U.S.

4 Dividend Aristocrats to Buy in February

4 Dividend Aristocrats to Buy in February

Rising inflation and the Fed’s signal that it will raise interest rates multiple times this year fostered high market volatility last month. And although the major market indexes rose for the third consecutive trading session yesterday, many analysts expect the market to remain volatile this year. Given this backdrop, we…

Johnson & Johnson Whale Trades Spotted

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

This Is What Whales Are Betting On Johnson & Johnson

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson: Q4 Earnings Insights

Johnson & Johnson: Q4 Earnings Insights

Johnson & Johnson (NYSE:JNJ) reported its Q4 earnings results on Tuesday, January 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

5 Stocks To Watch For January 25, 2022

5 Stocks To Watch For January 25, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Johnson & Johnson (NYSE: JNJ) to report quarterly earnings at $2.12 per share on revenue of $25.29 billion before the opening bell. Johnson & Johnson shares fell 0.3% to $162.50 in after-hours trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Johnson & Johnson's Earnings: A Preview

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-01-25. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will likely report an Earnings Per Share (EPS) of $2.12.

3 Pharmaceutical Stocks to Buy for the Long-Term

The global pharmaceutical industry is expected to witness stable growth over the long term, owing to the rising medical needs of an aging population and consistent innovations in the treatment of chronic ailments. So, we think it could be wise to scoop up shares of quality pharmaceutical stocks Johnson &…

Best Dividend Kings for Decades of Dividend Growth

Dividend Kings are the crème de la crème of dividend growers and should be top of mind for any investor who puts income stability above all else.

1 … 12 13 14 15

Organisations

US Federal Reserve

Johnson & Johnson (

Eli Lilly and Company

Johnson & Johnson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

374,541 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play